Summary of SGHT Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue:: $23.4 million, a 20% increase year-over-year, marking the strongest quarterly growth rate in three years.

Interventional Glaucoma Revenue:: $20.7 million, up 8% year-over-year, driven by increased volume and active accounts.

Interventional Dry Eye Revenue:: $2.7 million, nearly doubling from $1.4 million in Q1 2026.

Gross Margin:: 91%, an increase from 85% in the prior year, aided by $1.4 million in tariff refunds.

Operating Expenses:: $25.3 million, down 11% year-over-year due to lower personnel costs and stock-based compensation.

Net Loss:: $4.4 million, a 63% improvement from $11.9 million in Q2 2025.

Cash Position:: $79.8 million at quarter-end, down from $85 million in Q1 2026, with cash usage significantly reduced to $1.4 million (excluding one-time items).

2Strategic Updates and Business Highlights

Interventional Dry Eye:: Achieved record revenue with strong adoption of TearCare, increasing patient lives with access to reimbursement from 10.4 million to 14.5 million. The company raised its revenue guidance for this segment to $9 million - $11 million.

Interventional Glaucoma:: Continued growth with OMNI, supported by an expanding customer base and successful clinical experiences. The company narrowed revenue guidance for this segment to $79 million - $81 million.

Product Development:: Announced the upcoming launch of OMNI Ultra, featuring advancements based on surgeon feedback, expected to enhance customer engagement and market penetration.

Market Access:: Engaged with multiple Medicare Administrative Contractors (MACs) to improve reimbursement access for TearCare, with expectations for additional payer coverage in the second half of 2026.

3Forward Guidance and Outlook

Full-Year 2026 Revenue Guidance:: Raised to $88 million - $92 million, reflecting growth of 14% to 19% compared to 2025.

Adjusted Operating Expense Guidance:: Reduced to $92 million - $94 million, indicating a disciplined approach to spending while supporting growth initiatives.

Q3 2026 Expectations:: Anticipate total revenue growth in the mid to high teens, with Interventional Glaucoma expected to grow in the mid-single digits and Interventional Dry Eye projected at approximately $3 million.

4Bad News, Challenges, or Points of Concern

Cash Flow Management:: While cash usage improved, the company still reported a net loss, indicating ongoing challenges in achieving profitability.

Market Dynamics:: The interventional glaucoma market faces tougher comparisons in the second half of the year, which may impact growth rates.

Payer Engagement:: Although progress is being made, the timing of payer decisions remains uncertain and could affect the anticipated growth in the Interventional Dry Eye segment.

5Notable Q&A Insights

Market Stability:: Management expressed confidence in the stability of the interventional glaucoma market, noting a growing interventional mindset among providers.

Utilization Trends:: There is evidence of increasing utilization across a broader range of accounts in the Interventional Dry Eye segment, although top accounts continue to drive a significant share of volume.

Competitive Landscape:: TearCare is positioned uniquely with robust clinical data supporting reimbursement, with no significant competitive response noted from cash-pay alternatives like LipiFlow or iLux.

Operational Discipline:: Management emphasized a balanced approach to growth and expense management, indicating confidence in their operational efficiency and ability to achieve cash flow breakeven without additional equity capital. This summary encapsulates the key points from the earnings call, highlighting both the positive developments and the challenges facing Sight Sciences as it navigates its growth trajectory.